Acute promyelocytic leukemia
Drug research and approvals for acute promyelocytic leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 9 studies of acute promyelocytic leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 2 approved and 6 open orphan designations naming it.
- Recruiting worldwide: 9
- Trials authorized in Canada: 0
- FDA orphan approvals: 2
- EU medicines: 0
- Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute…NCT07503730 · Phase 3 · First Affiliated Hospital Xi'an Jiaotong University · starts Jun 1, 2025
- Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaNCT07504458 · Phase 3 · Quetzal Therapeutics · starts Jun 8, 2026
- Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic LeukemiaNCT06982274 · Phase 2 · Instituto do Cancer do Estado de São Paulo · starts Oct 20, 2023
- Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic LeukemiaNCT05881265 · Phase 2 · Shanghai Jiao Tong University School of Medicine · starts May 15, 2023
- RWE of 1st Line Treatment With ATO/ATRA for Adult APLNCT04897490 · Not reported · Grupo Argentino de Tratamiento de la Leucemia Aguda · starts Mar 1, 2021
- Treatment Study for Children and Adolescents With Acute Promyelocytic LeukemiaNCT04793919 · Phase 2 · Associazione Italiana Ematologia Oncologia Pediatrica · starts Oct 9, 2019
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and…NCT02390752 · Phase 1 · National Cancer Institute (NCI) · starts Apr 29, 2015
- PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed…NCT02390635 · Phase 1 · M.D. Anderson Cancer Center · starts Jul 15, 2020
- Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated…NCT01409161 · Phase 2 · M.D. Anderson Cancer Center · starts Oct 5, 2011
Approved 2
- TretinoinRetinoic acid receptor agonist
- Arsenic trioxideThioredoxin reductase 1 inhibitor
Phase 3 8
- CytarabineDNA inhibitor
- IdarubicinDNA topoisomerase II alpha inhibitor
- MethotrexateDihydrofolate reductase inhibitor
- MercaptopurineAmidophosphoribosyltransferase inhibitor
- DaunorubicinDNA topoisomerase II alpha inhibitor
- Indigo
- HydroxyureaRibonucleoside-diphosphate reductase RR1 inhibitor
- MitoxantroneDNA topoisomerase II alpha inhibitor
Phase 2 10
- Gemtuzumab ozogamicinMyeloid cell surface antigen CD33 binding agent
- Bortezomib26S proteasome inhibitor
- TamibaroteneRetinoic acid receptor beta agonist
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- RomidepsinHistone deacetylase inhibitor
- NRX195183Retinoic acid receptor alpha agonist
- VenetoclaxApoptosis regulator Bcl-2 inhibitor
- Ascorbic acidSupplement
- Gelatin
- Tucidinostat
Phase 1 or earlier 11
- VorinostatHistone deacetylase 1 inhibitor
- IsotretinoinRetinoic acid receptor agonist
- DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- ClofarabineRibonucleoside-diphosphate reductase RR1 inhibitor
- UCN-01Cyclin-dependent kinase 2 inhibitor
- GadoliniumDiagnostic (when bound to a chelating agent)
- FludeoxyglucoseDiagnostic agent
- Perifosine
- Vadastuximab talirine
- BMS-214662
How its trials ended
103 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 33 whose ending is known, 52% met their primary endpoint, 6% missed it and 42% stopped early.
- Completed, result not reported3534%
- Status unknown1817%
- Met its primary endpoint1717%
- Ongoing1717%
- Stopped: other or unclear77%
- Stopped: enrollment or feasibility44%
- Missed its primary endpoint22%
- Stopped: funding22%
- Stopped: sponsor or business decision11%
| Jan 12, 2018 | TrisenoxIn combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is… | Teva Branded Pharmaceutical Products R&D, Inc. | Approved |
| Sep 25, 2000 | TrisenoxFor induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed… | Teva Branded Pharmaceutical Products R&D, Inc. | Approved |
| Nov 19, 2024 | Arsenic trioxideTreatment of acute promyelocytic leukemia | SDK Therapeutics, Inc. | Designated |
| Nov 2, 2015 | Arsenic trioxideTreatment of acute promyelocytic leukemia. | Quetzal Therapeutics, LLC | Designated |
| Nov 2, 2010 | MenatetrenoneTreatment of acute promyelocytic leukemia. | NBI Pharmaceuticals, Inc. | Designated |
| Oct 11, 2007 | TamibaroteneTreatment of acute promyelocytic leukemia (APL). | CytRx Corporation | Designated |
| Jan 19, 2000 | PhenylbutyrateTreatment of acute promyelocytic leukemia. | Elan Drug Delivery, Inc. | Designated |
| Apr 10, 1992 | AlitretinoinTreatment of acute promyelocytic leukemia | Ligand Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA